ArticleFrontiers in neurology2025
Humanistic burden and medical care patterns of real-world patients with myasthenia gravis in Japan.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Patient- and Caregiver-Reported Burden and Quality of Life in Generalised Myasthenia Gravis: A Multinational Real-World Survey in the Asia-Pacific Region.Neurology and therapy · 2026Article
- Treatment Patterns in Patients with Late-Onset Myasthenia Gravis in Japan: An Insurance Claims Database Study.Drugs - real world outcomes · 2026Article
- Usefulness of Early Treatment with Efgartigimod in Patients with Generalized Myasthenia Gravis Complicated by Cardiovascular Disease: A Case Report.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myasthenia gravis (MG) is a rare autoimmune disease characterized by skeletal muscle weakness. As limited real-world data are available in Japan, we aimed to describe the humanistic burden of disease (primary aim), mainly with regards to health-related quality of life (HRQoL), and treatment patterns (secondary aim) in patients with generalized MG (gMG). Methods: Data were drawn from the Adelphi Real World MG Disease Specific Programme™, a cross-sectional survey of neurologists and their patients in Japan from August 2023 and January 2024. Analyses were descriptive. Results: Overall, 40 neurologists reported data for 128 patients, where 29 patients had self-reported data. Mean (standard deviation) patient age was 57.9 (16.0) years and 53.9% were female. At data collection, 98.4% of patients were receiving maintenance therapy (including novel treatments). Nonsteroidal immunosuppressant therapies were used at first-line of therapy in 54.5% of cases ( Conclusion: Most patients in this Japanese cohort with gMG received maintenance therapy and the time from symptom onset to diagnosis was relatively short. However, impaired HRQoL remained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.